Intensity Therapeutics Faces Delisting Concerns

Ticker: INTS · Form: 8-K · Filed: May 20, 2025 · CIK: 1567264

Intensity Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyIntensity Therapeutics, Inc. (INTS)
Form Type8-K
Filed DateMay 20, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: delisting, compliance, exchange-rules

Related Tickers: INTY

TL;DR

INTENSITY THERAPEUTICS (INTY) might get delisted - big trouble for shareholders.

AI Summary

Intensity Therapeutics, Inc. filed an 8-K on May 20, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicates a potential issue with the company's compliance with stock exchange listing requirements as of May 19, 2025.

Why It Matters

This filing signals potential financial distress or non-compliance with exchange rules, which could lead to the stock being delisted, severely impacting liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards is a severe warning sign that can lead to significant stock price declines and reduced trading activity.

Key Players & Entities

  • INTENSITY THERAPEUTICS, INC. (company) — Registrant
  • 001-41109 (company) — SEC File Number
  • 46-1488089 (company) — IRS Employer Identification No.
  • May 19, 2025 (date) — Earliest event reported
  • May 20, 2025 (date) — Date of Report

FAQ

What specific listing rule or standard has Intensity Therapeutics failed to satisfy?

The filing does not specify the exact rule or standard that Intensity Therapeutics has failed to satisfy, only that a notice has been issued.

What is the potential consequence of failing to meet listing standards?

The consequence of failing to meet listing standards can include delisting from the stock exchange, which would significantly impact the stock's liquidity and trading.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on May 19, 2025.

What is the company's principal executive office address?

The company's principal executive office is located at 1 Enterprise Drive, Suite 430, Shelton, CT 06484-4779.

What is the company's SIC code?

The company's Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 20, 2025 regarding INTENSITY THERAPEUTICS, INC. (INTS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.